Overview
Cellebrite Q2 revenue grows 18% yr/yr, beating analyst expectations, per LSEG data
Adjusted EBITDA for Q2 beats estimates, reflecting a 29% increase, per LSEG data
Net income for Q2 misses analyst expectations, per LSEG data
Outlook
Cellebrite expects Q3 revenue between $121 mln and $126 mln
Full-year 2025 revenue forecasted at $465 mln to $475 mln
Company anticipates Q3 adjusted EBITDA of $31 mln to $34 mln
Full-year adjusted EBITDA expected to be $118 mln to $123 mln
Pending acquisition of Corellium expected to enhance digital investigation capabilities
Result Drivers
SUBSCRIPTION REVENUE - Subscription revenue increased 21% yr/yr, contributing to overall revenue growth
GROSS PROFIT - GAAP gross profit and gross margin of $95.6 million and 84.4%, respectively; Non-GAAP gross profit and gross profit margin of $96.4 million and 85.1%, respectively
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $113.28 mln | $112.20 mln (8 Analysts) |
Q2 Net Income | Miss | $19.48 mln | $25.40 mln (5 Analysts) |
Q2 Adjusted EBITDA | Beat | $27.88 mln | $27 mln (7 Analysts) |
Q2 Gross Margin | 84.4% | ||
Q2 Cash Flow from Operating Activities | $32.58 mln | ||
Q2 Operating Income | $14.42 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Cellebrite DI Ltd is $24.50, about 42.9% above its August 13 closing price of $13.99
The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 45 three months ago
Press Release: ID:nGNX2GF7Gt
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)